Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

COX-2 Inhibitors Celecoxib and Rofecoxib Prevent Oxidative DNA Fragmentation

CHRISTOPH MATTHIAS, MARIE THERESE SCHUSTER, SABINA ZIEGER and ULRICH HARRÉUS
Anticancer Research May 2006, 26 (3A) 2003-2007;
CHRISTOPH MATTHIAS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: christoph.matthias{at}med.uni-muenchen.de
MARIE THERESE SCHUSTER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SABINA ZIEGER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ULRICH HARRÉUS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Cyclooxygenase (COX) is the key regulatory enzyme in prostaglandin (PG) synthesis and is up-regulated in many premalignant and malignant lesions. The aim of this study was to investigate the in vitro DNA protective or damaging effects of COX-2 inhibitors using the single-cell gel electrophoresis (Comet) assay. Materials and Methods: Cells from miniorgan cultures of pharyngeal mucosa from 30 patients were incubated once or five times with the COX-2 inhibitors celecoxib and rofecoxib. After treatment with H2O2, DNA fragmentation was determined. Results: DNA strand-breaks were significantly reduced in cells pre-incubated with COX-2 inhibitors. Repeated incubation with celecoxib showed the strongest effect. This direct influence on DNA repair could be excluded by implementing DNA repair steps into the Comet assay. Conclusion: The findings suggest that, in addition to the known influence of COX-2 inhibitors on immune surveillance, neo-angiogenesis and cell proliferation, these substances may express a direct antimutagenic effect in conditions of oxidative stress.

  • Cyclooxygenase inhibitor
  • Comet assay
  • chemoprevention
  • antimutagenic effect
  • DNA repair

Footnotes

  • Received December 5, 2005.
  • Revision received March 24, 2006.
  • Accepted April 10, 2006.
  • Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 26, Issue 3A
May-June 2006
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
COX-2 Inhibitors Celecoxib and Rofecoxib Prevent Oxidative DNA Fragmentation
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
7 + 8 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
COX-2 Inhibitors Celecoxib and Rofecoxib Prevent Oxidative DNA Fragmentation
CHRISTOPH MATTHIAS, MARIE THERESE SCHUSTER, SABINA ZIEGER, ULRICH HARRÉUS
Anticancer Research May 2006, 26 (3A) 2003-2007;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
COX-2 Inhibitors Celecoxib and Rofecoxib Prevent Oxidative DNA Fragmentation
CHRISTOPH MATTHIAS, MARIE THERESE SCHUSTER, SABINA ZIEGER, ULRICH HARRÉUS
Anticancer Research May 2006, 26 (3A) 2003-2007;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Chemoprevention by Celecoxib and Mutagen Sensitivity of Cyclin D1 in Patients with Oropharyngeal Carcinoma
  • Reduction of DNA Damage by Curcumin and Celecoxib in Epithelial Cell Cultures of the Oropharynx after Incubation with Tobacco Smoke Condensate
  • Google Scholar

More in this TOC Section

  • Targeting AURKB Attenuates Tumor Growth in MYC-driven Lung Adenocarcinoma
  • Novel NOTCH1-unmutated T-ALL Cell Line With Suppressed Growth by Gamma-secretase Inhibitors
  • Beneficial Effects of Combining an Immune Checkpoint Inhibitor With Proton Radiation, OXi4503, or Hyperthermia in a Murine Solid Tumor Model
Show more Experimental Studies
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire